Related Experiment Video

Updated: Jan 3, 2026

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

7.7K

Naringin inhibits thyroid cancer cell proliferation and induces cell apoptosis through repressing PI3K/AKT pathway

Jun Zhou1, Liang Xia1, Yu Zhang2

  • 1Department of Nuclear Medicine, Wuhan Central Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430014, China.

Pathology, Research and Practice
|November 16, 2019
PubMed

Insights

Naringin exhibits anti-tumor properties against thyroid cancer (TC) by inhibiting cell proliferation and inducing apoptosis. It modulates key genes and the PI3K/AKT pathway, suggesting potential therapeutic value for TC treatment.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • Thyroid cancer (TC) remains a significant health concern with ongoing research for novel therapeutic agents.
  • Naringin, a natural flavonoid, has demonstrated various biological activities, prompting investigation into its anti-cancer potential.

Purpose of the Study:

  • To investigate the anti-tumor effects of naringin in thyroid cancer (TC) cell lines.
  • To elucidate the underlying molecular mechanisms, including effects on cell proliferation, apoptosis, and signaling pathways.

Main Methods:

  • Thyroid cancer cell lines (TPC-1 and SW1736) were treated with varying concentrations of naringin.
  • Cell proliferation was assessed using MTT assay; apoptosis was analyzed by flow cytometry.
  • Gene expression related to proliferation and apoptosis (cyclin D1, c-Myc, survivin, Caspase3, Bcl-2, Bax) was measured by qRT-PCR and Western blot.
  • PI3K/AKT pathway activation was also analyzed.

Main Results:

  • Naringin significantly inhibited TC cell proliferation and induced apoptosis in a dose- and time-dependent manner.
  • Naringin modulated the expression of key apoptosis-related genes, increasing Bax, Caspase3, and cleaved Caspase3, while decreasing cyclin D1, c-Myc, survivin, and Bcl-2.
  • Naringin suppressed the activation of the PI3K/AKT signaling pathway in TC cells.

Conclusions:

  • Naringin demonstrates potent anti-tumor effects against thyroid cancer cells.
  • These effects are mediated by the inhibition of cell proliferation, induction of apoptosis, regulation of specific genes, and suppression of the PI3K/AKT pathway.
  • Naringin shows promise as a potential therapeutic agent for thyroid cancer, warranting further investigation.
Keywords:
ApoptosisNaringinPI3K/AKT pathway.Papillary thyroid cancerProliferation

More Related Videos

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.2K
Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity09:32

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

364

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.2K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
8.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.6K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
496
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
9.7K